Using Siltuximab to treat antibody-mediated rejection after lung transplants
A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection after Lung Transplantation
This study is looking at how well Siltuximab, a medication that helps with immune responses, can help patients who are having problems after a lung transplant due to antibody-mediated rejection, with the goal of improving their health and recovery.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Utah NIH-funded |
| Lab location | 1 site (Salt Lake City, United States) |
| Project ID | NIH-10925203 on NIH RePORTER |
What this research studies
This research investigates the use of Siltuximab, a medication that targets specific immune responses, to treat patients experiencing antibody-mediated rejection (AMR) after lung transplantation. AMR is a serious condition that can lead to chronic lung allograft dysfunction and significantly impacts survival rates. The study aims to assess the safety and effectiveness of Siltuximab in improving outcomes for these patients. Participants will be closely monitored to evaluate their response to the treatment and any potential side effects.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have undergone lung transplantation and are experiencing symptoms of antibody-mediated rejection.
Not a fit: Patients who have not received a lung transplant or those without evidence of antibody-mediated rejection may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could improve survival rates and quality of life for lung transplant recipients facing antibody-mediated rejection.
How similar studies have performed: While there have been various treatments for AMR, this approach using Siltuximab is novel and has not been extensively tested in randomized controlled trials.
Where this research is happening
Salt Lake City, United States
- University of Utah — Salt Lake City, United States (Active)
Researchers
- Principal investigator: Hachem, Ramsey — University of Utah
- Study coordinator: Hachem, Ramsey
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.